SynthesisBioMed research international2022
Risk and Prognostic Factors for BRAF
Synthesis in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis.Frontiers in endocrinology · 2023Pooled it
- UCHL5 suppresses thyroid carcinoma progression via ZRANB1 stabilization and ferroptosis regulation.Cancer biology & therapy · 2026Article
- Treatment strategies for unilateral papillary thyroid carcinoma with ipsilateral cervical lymph node metastasis: a narrative review.Gland surgery · 2026Review
- IL1β Functions as a Tumor Suppressor in Papillary Thyroid Carcinoma via the SMDT1-MAPK Signaling Axis.Cancers · 2026Article
- Development and validation of theAnnals of medicine and surgery (2012) · 2026Article
- Article
- Independent Prognostic Value ofCancers · 2026Review
- Preoperative Co-Mutation of BRAFCancer medicine · 2026Article
- Isthmic papillary thyroid microcarcinoma: clinicopathological features and prognostic factors following isthmusectomy based on tumor size stratification.Discover oncology · 2026Article
- The FOXE1 rs965513 polymorphism: a pleiotropic risk locus associated with thyroid function, BRAFScientific reports · 2026Article
- Nomogram for predicting papillary thyroid carcinoma risk combined with clinical, biochemical and ultrasonographic indicators.BMC cancer · 2026Article
- Article
- Fine Needle Aspiration Cytology of Papillary Thyroid Carcinoma: Association of Cytological Features with Tumor Invasiveness in 43 Cases.Iranian journal of pathology · 2026Article
- The role of plectin as a druggable target in papillary thyroid carcinoma: therapeutic potential of troglitazone.Frontiers in immunology · 2026Article
- Papillary thyroid carcinoma and primary aldosteronism: A new syndrome or a mere association?World journal of clinical cases · 2025Article
- Article
- Construction and validation of risk models of prognostic genes associated with parthanatos in papillary thyroid carcinoma based on bioinformatics.Discover oncology · 2025Article
- Clinical Implications and Application of Molecular Testing in the Diagnosis and Management of Thyroid Nodules in the Chinese Population.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Observational
- Progress in Drug-targeted Therapy for Papillary Thyroid Carcinoma.Current oncology reports · 2025Review
- Characterization of a novel four-miRNA signature in papillary thyroid carcinoma: Integrating molecular profiling, hormonal regulation, and diagnostic implications in populations with rising PTC incidence.Cancer biomarkers : section A of Disease markers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC) worldwide has been increasing rapidly year by year, with the incidence rate increasing 6% annually. PTC has become the malignant tumor with the highest growth rate in the world that fourteen PTC-related mutant genes have been identified. Whether the BRAF Methods: A total of 9,908 papillary thyroid carcinoma patients with average 74.6% BRAF Results: The following variables were associated with an increased risk of BRAF Conclusion: Our systematic review identified the following significant risk factors of BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.